fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Brinzolamide

All products: Limited Use (codes 171, 172, 387)

Azopt · DIN 02238873 · 1% · Oph suspension

Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Azopt · DIN 02238873 Manufacturer: Novartis Pharma Canada Inc.; listing date 2000-01-17 Health Canada: Marketed since 2018-03-14 · brand AZOPT · ATC S01EC04 BRINZOLAMIDE · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Azopt: Formulary list price $3.56 per unit (the source does not state the unit; exact figure $3.5560). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238873)

Source record
DIN 02238873: Azopt Raw flags: sec12=Y, sec3=Y Item: 523600096; group id 616; item number 1583; lccId 00083; manufacturer id NOV Source form: Oph Susp; strength: 1% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.5560; ministry $3.5560 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238873 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62313
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238873
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01E, S01EC): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Dorzolamide (Trusopt): limited Use 171, 172, 387
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit

9 more in the class list below

Brinzolamide & brimonidine tartrate

All products: Limited Use (codes 393, 466)

Simbrinza · DIN 02435411 · 1.0% & 0.2% · Oph suspension-10mL Pk

Limited Use, Reason for Use code 466, 393 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 466, 393 required
Write on scriptone applicable Reason for Use code, 466 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 466, 393
Reason for Use code 466 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Simbrinza · DIN 02435411 Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-10-29 Health Canada: Marketed since 2018-04-18 · brand SIMBRINZA · ATC S01EC54 BRINZOLAMIDE, COMBINATIONS, S01EC54 BRINZOLAMIDE, COMBINATIONS · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V, BRIMONIDINE TARTRATE 0.2 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Simbrinza: Formulary list price $50.69 per unit (the source does not state the unit; exact figure $50.6900). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435411)

Source record
DIN 02435411: Simbrinza Raw flags: sec12=Y, sec3=Y Item: 523600143; group id 617; item number 1584; lccId 00258; manufacturer id NOV Source form: Oph Susp-10mL Pk; strength: 1.0% & 0.2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.6900; ministry $50.6900 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435411 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91973
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435411
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01E, S01EC): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Dorzolamide (Trusopt): limited Use 171, 172, 387
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit

9 more in the class list below

Brinzolamide & timolol maleate

All products: Limited Use (codes 310, 393)

Azarga · DIN 02331624 · 1% & 0.5% · Oph suspension-5mL Pk

Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 310, 393 required
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Azarga · DIN 02331624 Manufacturer: Novartis Pharma Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2018-03-09 · brand AZARGA · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Suspension · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, BRINZOLAMIDE 1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Azarga: Formulary list price $20.40 per unit (the source does not state the unit; exact figure $20.4000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02331624)

Source record
DIN 02331624: Azarga Raw flags: sec12=Y, sec3=Y Item: 523600131; group id 618; item number 1585; lccId 00204; manufacturer id NOV Source form: Oph Susp-5mL Pk; strength: 1% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $20.4000; ministry $20.4000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02331624 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81730
Shortage status: resolved shortage (ended April 3, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02331624
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01E, S01EC): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Dorzolamide (Trusopt): limited Use 171, 172, 387
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, not a benefit

9 more in the class list below

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk

LATANOPROST

· 9 products · Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 18 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: elevated intraocular pressure, intraocular pressure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BIMATOPROST · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7)  the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00049647.PDF; date January 28, 2019; DIN 02429063; fetched 2026-09-10 Product monograph TIMOLOL MALEATE · Listed, not a benefit (5), General benefit (11)  the reduction of elevated intraocular pressure PM: https://pdf.hres.ca/dpd_pm/00067983.PDF; date OCT 28, 2016; DIN 00451207; fetched 2026-09-10 Product monograph TRAVOPROST · Limited Use, codes 171, 172, 387 INDICATIONS AND CLINICAL USE Sandoz Travoprost is indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00051001.PDF; date May 7, 2019; DIN 02413167; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS AZOPT® (brinzolamide ophthalmic suspension) is indicated for: • the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of AZOPT in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00069562.PDF PM date: OCT 23, 1998 Source product: AZOPT; DIN 02238873; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS SIMBRINZA (brinzolamide / brimonidine tartrate ophthalmic suspension) is indicated for: • the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction AND when the use of SIMBRINZA is considered appropriate. 1.1 Pediatrics Paediatrics (< 18 years of age): The safety and efficacy of SIMBRINZA has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. (see 2 CONTRAINDICATIONS and 7.1.3, Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00068869.PDF PM date: DEC 23, 2022 Source product: SIMBRINZA; DIN 02435411; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS AZARGA® (brinzolamide/timolol ophthalmic suspension) is indicated for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction and when the use of AZARGA is considered appropriate. 1.1 Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00068866.PDF PM date: DEC 23, 2022 Source product: AZARGA; DIN 02331624; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18